Beta-blockers in atrial fibrillation—trying to make sense of unsettling results

Atrial fibrillation is closely associated with heart failure and adversely affects outcomes. Beta-blockers are strongly recommended to avoid rapid ventricular conduction and tachycardia-induced cardiomyopathy. In this Viewpoint article, we discuss an emerging body of evidence that questions beta-blo...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Markus, Lustgarten, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
View Point
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935022/
https://www.ncbi.nlm.nih.gov/pubmed/36748952
http://dx.doi.org/10.1093/europace/euad010
_version_ 1784889993885384704
author Meyer, Markus
Lustgarten, Daniel
author_facet Meyer, Markus
Lustgarten, Daniel
author_sort Meyer, Markus
collection PubMed
description Atrial fibrillation is closely associated with heart failure and adversely affects outcomes. Beta-blockers are strongly recommended to avoid rapid ventricular conduction and tachycardia-induced cardiomyopathy. In this Viewpoint article, we discuss an emerging body of evidence that questions beta-blockers as a preferred rate-control therapy in patients with atrial fibrillation.
format Online
Article
Text
id pubmed-9935022
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-99350222023-02-17 Beta-blockers in atrial fibrillation—trying to make sense of unsettling results Meyer, Markus Lustgarten, Daniel Europace View Point Atrial fibrillation is closely associated with heart failure and adversely affects outcomes. Beta-blockers are strongly recommended to avoid rapid ventricular conduction and tachycardia-induced cardiomyopathy. In this Viewpoint article, we discuss an emerging body of evidence that questions beta-blockers as a preferred rate-control therapy in patients with atrial fibrillation. Oxford University Press 2023-02-07 /pmc/articles/PMC9935022/ /pubmed/36748952 http://dx.doi.org/10.1093/europace/euad010 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle View Point
Meyer, Markus
Lustgarten, Daniel
Beta-blockers in atrial fibrillation—trying to make sense of unsettling results
title Beta-blockers in atrial fibrillation—trying to make sense of unsettling results
title_full Beta-blockers in atrial fibrillation—trying to make sense of unsettling results
title_fullStr Beta-blockers in atrial fibrillation—trying to make sense of unsettling results
title_full_unstemmed Beta-blockers in atrial fibrillation—trying to make sense of unsettling results
title_short Beta-blockers in atrial fibrillation—trying to make sense of unsettling results
title_sort beta-blockers in atrial fibrillation—trying to make sense of unsettling results
topic View Point
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935022/
https://www.ncbi.nlm.nih.gov/pubmed/36748952
http://dx.doi.org/10.1093/europace/euad010
work_keys_str_mv AT meyermarkus betablockersinatrialfibrillationtryingtomakesenseofunsettlingresults
AT lustgartendaniel betablockersinatrialfibrillationtryingtomakesenseofunsettlingresults

Ejemplares similares